睿知中国医院研究地图
候选清单

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Mts105 for Advanced Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06689540,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;

    入选标准第 1 条

  3. Child-Pugh Score ≤ 6

    入选标准第 6 条

  4. Received any investigational drug within 4 weeks prior to the first dose.

    排除标准第 4 条

    Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.

    排除标准第 5 条

    Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.

    排除标准第 6 条

    Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.

    排除标准第 7 条

    Unresolved toxicity from prior anticancer therapy (> grade 1, according to CTCAE v5.0).

    排除标准第 11 条

  5. ECOG score ≤ 1

    入选标准第 7 条

  6. Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10\^9/L;Lymphocyte count ≥ 0.5 × 10\^9/L;Hemoglobin ≥ 90 g/L;Platelet count ≥ 75 × 10\^9/L;

    入选标准第 9 条

    Liver function:Total bilirubin ≤ 2.5 mg/dL;Albumin ≥ 28 g/L;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;

    入选标准第 10 条

    Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL/min (as determined by the CKD-EPI formula);Urinary protein < 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g

    入选标准第 12 条

  7. Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).

    入选标准第 4 条

  8. For HBV-associated HCC:

    排除标准第 17 条

    HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU/mL.

    排除标准第 18 条

    HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU/mL.

    排除标准第 19 条

    Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.

    排除标准第 20 条

    Positive for human immunodeficiency virus (HIV+).

    排除标准第 21 条

  9. Women who are pregnant or breastfeeding.

    排除标准第 25 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06689540,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;
  2. Positive for GPC3 expression per immunohistochemical (IHC) staining.
  3. Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, and/or anti vascular endothelial growth factor agent).
  4. Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).
  5. Barcelona Clinical Liver Cancer Stage B or C (BCLC B/C)
  6. Child-Pugh Score ≤ 6
  7. ECOG score ≤ 1
  8. Adequate organ and bone marrow function as defined by the following laboratory criteria:
  9. Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10\^9/L;Lymphocyte count ≥ 0.5 × 10\^9/L;Hemoglobin ≥ 90 g/L;Platelet count ≥ 75 × 10\^9/L;
  10. Liver function:Total bilirubin ≤ 2.5 mg/dL;Albumin ≥ 28 g/L;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;
  11. International Normalized Ratio (INR) ≤ 2.3;Oral anticoagulant therapy at a stable dose for at least 2 weeks. If oral warfarin is used, the patient must have an INR ≤ 3.0 and no bleeding events within 28 days prior to administration;
  12. Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL/min (as determined by the CKD-EPI formula);Urinary protein < 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g
  13. Cardiac function:Left ventricular ejection fraction (LVEF) ≥ 50%; No clinically significant abnormal ECG findings (chronic atrial fibrillation is allowed, provided it does not require medication);
  14. Capable of full communication with the investigator, with the ability to understand and comply with study requirements, and able to understand and sign the informed consent form (ICF).
  15. ≥18 years

排除标准:Exclusion Criteria:

  1. Any known active intracranial metastases, or brain metastases that have been treated for less than 4 weeks.
  2. Recent Antitumor Therapy:
  3. Treatment with any immune checkpoint inhibitor within 4 weeks (28 days) prior to the first dose.
  4. Received any investigational drug within 4 weeks prior to the first dose.
  5. Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.
  6. Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.
  7. Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.
  8. Received herbal or proprietary Chinese medicine for antitumor indications within 1 week prior to the first dose.
  9. Previously received experimental treatment targeting GPC3 (patients may be enrolled if they remain positive for GPC3 upon testing).
  10. History of liver transplantation or hematopoietic stem cell transplantation.
  11. Unresolved toxicity from prior anticancer therapy (> grade 1, according to CTCAE v5.0).
  12. Major surgery (other than biopsy) within 28 days prior to the first dose.
  13. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg).
  14. Class III-IV heart failure by New York Heart Association (NYHA) criteria within 6 months prior to the first dose, unstable angina, myocardial infarction, bypass surgery, stent placement, cerebral infarction, or clinically significant valvular heart disease.
  15. QTcF ≥ 450 ms in men and ≥ 470 ms in women (by Fridericia formula).
  16. Severe infection within 4 weeks before the first dose (excluding viral hepatitis), or any signs or symptoms of active infection within 2 weeks before the first dose, or patients requiring antibiotic treatment within 2 weeks (excluding local medications and prophylactic antibiotics); unexplained fever > 38.5°C before the first dose.
  17. For HBV-associated HCC:
  18. HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU/mL.
  19. HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU/mL.
  20. Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.
  21. Positive for human immunodeficiency virus (HIV+).
  22. Subjects requiring systemic corticosteroids (equivalent dose of prednisone > 10 mg/day) or other immunosuppressive drugs within 14 days prior to the first dose or during the study.
  23. History of autoimmune disease requiring systemic treatment within 2 years prior to the first dose.
  24. History of other malignancies within 2 years prior to the first dose (excluding cured skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or other cancers that the investigator believes are cured and have an extremely low risk of recurrence).
  25. Women who are pregnant or breastfeeding.
  26. Any other condition that, in the opinion of the investigator, makes participation in the study inappropriate.

引自 ClinicalTrials.gov, NCT06689540, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06689540,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06689540